NO20012690L - Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer - Google Patents
Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrerInfo
- Publication number
- NO20012690L NO20012690L NO20012690A NO20012690A NO20012690L NO 20012690 L NO20012690 L NO 20012690L NO 20012690 A NO20012690 A NO 20012690A NO 20012690 A NO20012690 A NO 20012690A NO 20012690 L NO20012690 L NO 20012690L
- Authority
- NO
- Norway
- Prior art keywords
- triglyceride levels
- alkanoic acids
- inhibiting angiogenesis
- serum glucose
- reducing serum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11039598P | 1998-12-01 | 1998-12-01 | |
| PCT/US1999/028483 WO2000032180A2 (en) | 1998-12-01 | 1999-12-01 | Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20012690D0 NO20012690D0 (no) | 2001-05-31 |
| NO20012690L true NO20012690L (no) | 2001-07-27 |
Family
ID=22332786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012690A NO20012690L (no) | 1998-12-01 | 2001-05-31 | Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US6555568B1 (tr) |
| EP (1) | EP1135124B1 (tr) |
| JP (1) | JP2002531398A (tr) |
| KR (1) | KR20010086075A (tr) |
| CN (1) | CN1368883A (tr) |
| AP (1) | AP2001002146A0 (tr) |
| AT (1) | ATE265210T1 (tr) |
| AU (1) | AU770925B2 (tr) |
| BG (1) | BG105531A (tr) |
| BR (1) | BR9915882A (tr) |
| CA (1) | CA2385845A1 (tr) |
| CZ (1) | CZ20011864A3 (tr) |
| DE (1) | DE69916881T2 (tr) |
| DZ (1) | DZ2953A1 (tr) |
| EE (1) | EE200100296A (tr) |
| HK (1) | HK1046372A1 (tr) |
| HU (1) | HUP0104953A3 (tr) |
| ID (1) | ID30037A (tr) |
| IL (1) | IL143247A0 (tr) |
| MX (1) | MXPA02003118A (tr) |
| NO (1) | NO20012690L (tr) |
| OA (1) | OA12035A (tr) |
| PL (1) | PL349016A1 (tr) |
| SK (1) | SK7352001A3 (tr) |
| TN (1) | TNSN99224A1 (tr) |
| TR (1) | TR200101539T2 (tr) |
| TW (1) | TW584560B (tr) |
| WO (1) | WO2000032180A2 (tr) |
| YU (1) | YU40101A (tr) |
| ZA (1) | ZA200104126B (tr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID27884A (id) * | 1998-03-31 | 2001-05-03 | Inst For Pharm Discovery Inc | Asam-asam indolealkanoat yang disubstitusikan. |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| AU2001238718A1 (en) * | 2000-03-02 | 2001-09-12 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| WO2001085983A2 (en) * | 2000-05-09 | 2001-11-15 | The Institute For Pharmaceutical Discovery Llc | Methods for testing compounds useful for treating diabetic complications |
| TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| JP4399253B2 (ja) | 2001-06-20 | 2010-01-13 | ワイス | プラスミノゲンアクチベーターインヒビター−１（ｐａｉ−１）のインヒビターとしての、置換されたインドール酸誘導体 |
| JP2006514640A (ja) | 2002-12-10 | 2006-05-11 | ワイス | プラスミノゲンアクティベータインヒビターのインヒビターとしての置換３−アルキル及び３−アリールアルキル１ｈ−イル酢酸誘導体 |
| UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| CA2509222A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| WO2004052855A2 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| DK1569901T3 (da) | 2002-12-10 | 2009-02-16 | Wyeth Corp | Aryl-, aryloxy- og alkoxysubstituerede 1H-indol-3-yl-glyoxylsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1) |
| WO2004098498A2 (en) | 2003-04-28 | 2004-11-18 | Bayer Pharmaceuticals Corporation | Indole acetic acid derivatives and their use as pharmaceutical agents |
| US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| PL1750862T3 (pl) | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
| WO2006023865A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| AU2005311826A1 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as PPAR active compounds |
| US7531568B2 (en) * | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
| JP2009504762A (ja) | 2005-08-17 | 2009-02-05 | ワイス | 置換インドール類およびそれらの使用方法 |
| US20070072904A1 (en) * | 2005-09-07 | 2007-03-29 | Jack Lin | PPAR active compounds |
| RU2458918C2 (ru) | 2006-07-22 | 2012-08-20 | Оксаген Лимитед | Соединения, обладающие антагонистической активностью по отношению к crth2 |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| EP2250161B1 (en) | 2008-01-18 | 2013-10-16 | Atopix Therapeutics Limited | Compounds having crth2 antagonist activity |
| US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| NZ789295A (en) | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
| US4283539A (en) | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
| US4363912A (en) | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
| US4442118A (en) * | 1981-07-23 | 1984-04-10 | Ayerst, Mckenna & Harrison, Inc. | Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid |
| GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| ES2032749T3 (es) | 1985-11-07 | 1993-03-01 | Pfizer Inc. | Acidos oxoftalazinil-aceticos heterociclicos. |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
| US4960785A (en) | 1988-12-16 | 1990-10-02 | Pfizer Inc. | Indolinone derivatives |
| US4868301A (en) | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| US5064852A (en) * | 1988-12-16 | 1991-11-12 | Pfizer Inc. | Indolinone derivatives |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| GB8916774D0 (en) * | 1989-07-21 | 1989-09-06 | Bayer Ag | New indole derivatives,a process for their preparation and their use in medicaments |
| US5304557A (en) | 1989-12-15 | 1994-04-19 | Pfizer Inc. | Substituted oxoophthalazinyl acetic acids and analogs thereof |
| US5312829A (en) * | 1990-05-21 | 1994-05-17 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives |
| US5236945A (en) | 1990-06-11 | 1993-08-17 | Pfizer Inc. | 1H-indazole-3-acetic acids as aldose reductase inhibitors |
| US5116753A (en) * | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
| GB9122590D0 (en) | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
| JP3195455B2 (ja) | 1993-01-06 | 2001-08-06 | ウェルファイド株式会社 | キノリン−３−酢酸誘導体、その製造法と用途 |
| US5391551A (en) | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
| WO1995006056A1 (en) | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| GB9317764D0 (en) * | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| TW401301B (en) * | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
| US5700819A (en) | 1994-11-29 | 1997-12-23 | Grelan Pharmaceutical Co., Ltd. | 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications |
| IL117208A0 (en) | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
| JPH09165371A (ja) | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
| ID27884A (id) * | 1998-03-31 | 2001-05-03 | Inst For Pharm Discovery Inc | Asam-asam indolealkanoat yang disubstitusikan. |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| AU2001238718A1 (en) * | 2000-03-02 | 2001-09-12 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
-
1999
- 1999-11-29 TN TNTNSN99224A patent/TNSN99224A1/fr unknown
- 1999-12-01 MX MXPA02003118A patent/MXPA02003118A/es not_active IP Right Cessation
- 1999-12-01 CZ CZ20011864A patent/CZ20011864A3/cs unknown
- 1999-12-01 WO PCT/US1999/028483 patent/WO2000032180A2/en not_active Application Discontinuation
- 1999-12-01 HU HU0104953A patent/HUP0104953A3/hu unknown
- 1999-12-01 CN CN99814023A patent/CN1368883A/zh active Pending
- 1999-12-01 TR TR2001/01539T patent/TR200101539T2/tr unknown
- 1999-12-01 DZ DZ990253A patent/DZ2953A1/xx active
- 1999-12-01 AU AU21616/00A patent/AU770925B2/en not_active Ceased
- 1999-12-01 JP JP2000584876A patent/JP2002531398A/ja active Pending
- 1999-12-01 EE EEP200100296A patent/EE200100296A/xx unknown
- 1999-12-01 CA CA002385845A patent/CA2385845A1/en not_active Abandoned
- 1999-12-01 ID IDW00200101404A patent/ID30037A/id unknown
- 1999-12-01 US US09/452,252 patent/US6555568B1/en not_active Expired - Fee Related
- 1999-12-01 PL PL99349016A patent/PL349016A1/xx not_active Application Discontinuation
- 1999-12-01 AP APAP/P/2001/002146A patent/AP2001002146A0/en unknown
- 1999-12-01 OA OA00100134A patent/OA12035A/en unknown
- 1999-12-01 DE DE69916881T patent/DE69916881T2/de not_active Expired - Lifetime
- 1999-12-01 SK SK735-2001A patent/SK7352001A3/sk unknown
- 1999-12-01 YU YU40101A patent/YU40101A/sh unknown
- 1999-12-01 EP EP99965955A patent/EP1135124B1/en not_active Expired - Lifetime
- 1999-12-01 KR KR1020017006865A patent/KR20010086075A/ko not_active Application Discontinuation
- 1999-12-01 IL IL14324799A patent/IL143247A0/xx unknown
- 1999-12-01 AT AT99965955T patent/ATE265210T1/de not_active IP Right Cessation
- 1999-12-01 BR BR9915882-5A patent/BR9915882A/pt not_active IP Right Cessation
-
2000
- 2000-02-01 TW TW088120912A patent/TW584560B/zh active
-
2001
- 2001-05-21 ZA ZA200104126A patent/ZA200104126B/en unknown
- 2001-05-22 BG BG105531A patent/BG105531A/xx unknown
- 2001-05-31 NO NO20012690A patent/NO20012690L/no not_active Application Discontinuation
-
2002
- 2002-11-02 HK HK02107989.6A patent/HK1046372A1/zh unknown
-
2003
- 2003-03-26 US US10/397,140 patent/US6964980B2/en not_active Expired - Fee Related
-
2005
- 2005-11-15 US US11/274,583 patent/US20060074114A1/en not_active Abandoned
-
2010
- 2010-08-30 US US12/871,304 patent/US20100324105A1/en not_active Abandoned
-
2011
- 2011-11-22 US US13/302,906 patent/US20120065203A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20012690L (no) | Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer | |
| PT1316620E (pt) | Processo de pr?-hidr?lise de biomassa | |
| IT1309069B1 (it) | Procedimento per il trattamento ad umido con acidi di dischi asemiconduttori. | |
| PL348105A1 (en) | Process for the preparation of glycidylesters of branched carboxylic acids | |
| NO20004900D0 (no) | Substituerte indolalkansyrer | |
| GB9820913D0 (en) | Method & apparatus for top to bottom expansion of tubulars | |
| EE04281B1 (et) | 8-metoksükinoloonkarboksüülhapete valmistamismeetod | |
| EP1200538A4 (en) | METHOD FOR TREATING PETROLEUMIC ACIDS | |
| NO20001777D0 (no) | Fremgangsmåte for fremstilling av substituerte 4-fenyl-4- cyanocykloheksankarboksylsyrer | |
| AU3436299A (en) | Process for the production of acetic acid and/or acetic anhydride | |
| NO991146L (no) | FremgangsmÕte ved overflatebehandling | |
| NO308418B1 (no) | FremgangsmÕte ved fremstilling av rustfritt stÕl | |
| PL336836A1 (en) | Method of obtaining aminoaryl sulphonic acids | |
| AU3959499A (en) | Process of purifying angiogenesis inhibitors | |
| ID28417A (id) | Metode memperbaiki permukaan produk logam | |
| NO20006383L (no) | Fremgangsmåte for behandling | |
| GB2333773B (en) | Process for the production of acetic anhydride | |
| NO994108D0 (no) | Fremgangsmåte ved fremstilling av 4H-4-okso-kinolizin-3-karboksylsyrederivater | |
| NO995678L (no) | Fremgangsmåte for fremstilling av 5-okso-3-fenyl-3- cykloheksenkarboksylsyre | |
| NO20005396L (no) | Fremgangsmåte for bioteknologisk oksydasjon av substituerte trimetylsykloheksenylforbindelser | |
| DE69908442D1 (de) | Verfahren zum Herstellen von Maleinsäureanhydrid | |
| NO20014449D0 (no) | Fremgangsmåte for fremstilling av 5-amino-8- alkylkinolonkarboksylsyrederivater og mellomprodukter ifremstillingen derav | |
| NO980194L (no) | Fremgangsmåte for vasking ved å anvende polykarboksylsyresalter | |
| HK1054249A1 (en) | Process for pre-hydrolysis of biomass | |
| HU9902599D0 (en) | Process for conservation of egg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |